Updated:
Graybug Vision
Graybug Vision (Nasdaq: GRAY) is a pharmaceutical company founded in 2011. It focuses on developing treatments for chronic retinal and optic nerve diseases.
Graybug Vision
Graybug Vision (Nasdaq: GRAY) is a pharmaceutical company founded in 2011. It focuses on developing treatments for chronic retinal and optic nerve diseases. Based in Redwood City, California.
General information
Firm type
other
Year founded
2010
Location
Region
North America
Country
United States
City
Redwood City
Corporate office
Redwood City, CA, United States
Principals
David Guyer
Co-Founder & CEO
Anthony Adamis
Co-Founder & Chief Scientific Officer
Geoffrey H. Gurtner
Board Member
Sector focus
Frequently asked questions
Who runs investment decisions at Graybug Vision?
Graybug Vision is a clinical-stage biopharmaceutical company run by CEO David Guyer and CSO Anthony Adamis. Investment in the company's pipeline is managed by its board of directors and executive team rather than a family office structure, as Graybug is a public company.
How does Graybug Vision generate drug development capital?
Graybug Vision raised venture funding from institutional investors including Blackstone Life Sciences and The Baupost Group before completing a $137M SPAC merger in 2021 (per SEC filings, 2021). The company has not disclosed additional large capital raises since then.
What is Graybug Vision's drug delivery approach?
Graybug's technology uses a microparticle-based depot system that releases active drug over months from a single injection. This is intended to treat retinal diseases like wet AMD and diabetic macular edema with reduced injection frequency compared to current standard-of-care monthly injections.
Has Graybug Vision approved any commercial drugs?
No. As of mid-2026, Graybug Vision has no commercially approved products. Its lead candidate GB-102 has completed Phase 2 trials but a Phase 3 program for diabetic macular edema was paused in 2024 following a dose-limiting toxicity signal.
Is Graybug Vision a family office investment vehicle?
Graybug Vision is a public biopharmaceutical company, not a family office. The company was founded by drug developers with prior success at Eyetech Pharmaceuticals, but it operates as a standalone business entity without identified single-family-office backing.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: